Zelia Correa, MD
Ophthalmology · Miami, FLNPI 1013934744
Payments from drug & device makers
Across 16 payments — averaging $203.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2K
- Immunocore Limited$274
- Genentech USA, Inc.$169
- Alcon$148
- Dompe US, Inc.$148
- Regeneron Healthcare Solutions, Inc.$147
- plus $417 from 6 others
What the payments were for
- Consulting fees$1,96060%
- Food & beverage$1,30340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $1,960 |
| Immunocore Limited | 3 | $274 |
| Genentech USA, Inc. | 2 | $169 |
| Alcon | 1 | $148 |
| Dompe US, Inc. | 1 | $148 |
| Regeneron Healthcare Solutions, Inc. | 2 | $147 |
| Pfizer | 1 | $104 |
| Ocular Therapeutix, Inc. | 1 | $100 |
| Astellas Pharma US Inc | 1 | $75 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Alimera Sciences, Inc. | 1 | $50 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,263 in reported general payments places this provider in the 60th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 24 | $1,534 |
| Ketorolac Tromethamine | 20 | $1,080 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 51 | $565 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $154 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Miami
- Guillermo AmescuaMiami$962K
- Felipe MedeirosMiami$935K
- Jennifer LohMiami$606K
- Jaclyn KovachMiami$590K
- William TrattlerMiami$580K
- Wilfredo LaraMiami$526K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$351K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.